Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B/5

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

390 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-30

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine a multidimensional signature (integrating frailty and patient-reported outcomes measures (PROMs) at entry into stage 4B/5 CKD) to improve prediction of renal death (dialysis, transplantation, conservative management, death).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Factors Influencing Risk of Progression of Chronic Kidney Disease

NCT03954470

Chronic Kidney Disease stage4

COMPLETED

Characteristics,Treatment Course and Prognosis of Patients Older Than 75 Yrs Old Reaching End Stage Renal Disease (PSPA)

NCT02910908

Kidney Failure, Chronic

COMPLETED

Evaluation of a Multidisciplinary Care Pathway on the Evolution of Renal Function in Patients With Advanced Chronic Kidney Disease

NCT06495385

Chronic Kidney Disease stage4 Chronic Kidney Disease Stage 5

ACTIVE_NOT_RECRUITING

Impact on Mortality of Screening for Kidney Disease Associated With a Specialized Intervention During Hospitalization in a Territorial Hospital Trust

NCT05033652

Acute Kidney Injury Chronic Kidney Diseases

UNKNOWN NA

Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

NCT02938611

Renal Insufficiency, Chronic

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 2019, 4,263 patients starting dialysis in France were aged 75 years or older. This elderly population, often with comorbidities, poses a number of challenges for nephrologists, both in terms of initiation and modalities of dialysis and access to transplantation. Dialysis may offer little benefit in terms of survival, often at the cost of a significant impact on quality of life and number of hospitalisations. There is a current trend to offer conservative treatment as an alternative to dialysis. However, there are no objective criteria to guide this decision and the uremic syndrome may distort certain clinical perceptions. The aim of this study is to determine whether an assessment that incorporates multiple dimensions, including those of frailty, can help the clinician determine the best course of treatment for the patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease Stage 5 Chronic Kidney Disease Stage 4B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with CKD stage 4B or 5 (first consultation with GFR \< 20 mL/min /1.73 m2 in CKD-EPI 2009).
* Fluency in French
* Membership of a French social security scheme
* Non-opposition from the subject to participate in the study

Exclusion Criteria

* Subjects with limited legal capacity.
* Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.
* Subjects with no social security coverage.
* Subjects judged by the investigator to be unlikely to comply with study procedures
* Subjects unable to understand the reasons for the study; psychiatric disorders judged by the investigator to be incompatible with inclusion in the study.

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No